Renaissance Capital logo

Ayala Pharmaceuticals Priced, Nasdaq: AYLA

Phase 2 biotech developing in-licensed Notch inhibitors for aggressive cancers.

Industry: Health Care

Latest Trade: $1.11 +0.02 (+2.1%)

First Day Return: +0.2%

Return from IPO: -92.7%

Industry: Health Care

We are a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations. Our differentiated development approach is predicated on identifying and addressing tumorigenic drivers of cancer, through a combination of our bioinformatics platform and next-generation sequencing to deliver targeted therapies to underserved patient populations. Our current portfolio of product candidates, AL101 and AL102, targets the aberrant activation of the Notch pathway with gamma secretase inhibitors. Gamma secretase is the enzyme responsible for Notch activation and, when inhibited, turns off the Notch pathway activation. Aberrant activation of the Notch pathway has long been implicated in multiple solid tumor and hematological cancers and has often been associated with more aggressive cancers. In cancers, Notch is known to serve as a critical facilitator in processes such as cellular proliferation, survival, migration, invasion, drug resistance and metastatic spread, all of which contribute to a poorer patient prognosis. AL101 and AL102 are designed to address the underlying key drivers of tumor growth, and our initial Phase 2 clinical data of AL101 suggest that our approach may address the shortcomings of existing treatment options. We believe that our novel product candidates, if approved, have the potential to transform treatment outcomes for patients suffering from rare and aggressive cancers.
more less
IPO News for Ayala Pharmaceuticals
more
IPO Data
IPO File Date 03/06/2020
Offer Price $15.00
Price Range $14.00 - $16.00
Offer Shares (mm) 3.7
Deal Size ($mm) $55
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
IPO Data
IPO Date 05/07/2020
Offer Price $15.00
Price Range $14.00 - $16.00
Offer Shares (mm) 3.7
Deal Size ($mm) $55
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
Underwriters
more
Company Data
Headquarters Rehovot, Israel
Founded 2017
Employees 29
Website www.ayalapharma.com